Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes

por Ratner, Robert, Han, Jenny, Nicewarner, Dawn, Yushmanova, Irina, Hoogwerf, Byron J, Shen, Larry
Publicado 2011

Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QT(c) interval in healthy subjects

por Darpö, Börje, Sager, Philip, MacConell, Leigh, Cirincione, Brenda, Mitchell, Malcolm, Han, Jenny, Huang, Wenying, Malloy, Jaret, Schulteis, Christine, Shen, Larry, Porter, Lisa
Publicado 2013

DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks

por Buse, John B., Drucker, Daniel J., Taylor, Kristin L., Kim, Terri, Walsh, Brandon, Hu, Hao, Wilhelm, Ken, Trautmann, Michael, Shen, Larry Z., Porter, Lisa E.
Publicado 2010